Bronchiectasis With Acute Exacerbation
13
6
6
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.7%
1 terminated out of 13 trials
66.7%
-19.9% vs benchmark
23%
3 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (13)
Azithromycin to Modify Bronchiectasis Exacerbation Risk
BASE: Bronchiectasis Severity and Exacerbation Risk Study
Bronchiectasis Phenotype Identification Model
Impact of Comorbidities and Severity on Outcomes in Bronchiectasis Excerbations
Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis
Exploring How Viral Infections Affect People With Chronic Lung Disease
A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
Comparing Active Cycle of Breathing Techniques (ACBT) and Aerobika in Treating Bronchiectasis in Korea
Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis.
A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting
Multi-omics Studies of Host-microbiome Interaction in Chronic Obstructive Pulmonary Disease and Bronchiectasis
Prevention of OM-85 on Bronchiectasis Exacerbation